Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.

Skibinski G, Nakamura K, Cookson MR, Finkbeiner S.

J Neurosci. 2014 Jan 8;34(2):418-33. doi: 10.1523/JNEUROSCI.2712-13.2014.

2.

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H.

Neuron. 2009 Dec 24;64(6):807-27. doi: 10.1016/j.neuron.2009.11.006.

3.

LRRK2 pathobiology in Parkinson's disease.

Martin I, Kim JW, Dawson VL, Dawson TM.

J Neurochem. 2014 Dec;131(5):554-65. doi: 10.1111/jnc.12949. Epub 2014 Oct 10. Review.

4.

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

Dusonchet J, Kochubey O, Stafa K, Young SM Jr, Zufferey R, Moore DJ, Schneider BL, Aebischer P.

J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.

5.

LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.

Huang Y, Song YJ, Murphy K, Holton JL, Lashley T, Revesz T, Gai WP, Halliday GM.

Acta Neuropathol. 2008 Dec;116(6):639-46. doi: 10.1007/s00401-008-0446-3. Epub 2008 Oct 21.

PMID:
18936941
6.

Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.

Liu J, Li T, Thomas JM, Pei Z, Jiang H, Engelender S, Ross CA, Smith WW.

Hum Mol Genet. 2016 Feb 15;25(4):672-80. doi: 10.1093/hmg/ddv504. Epub 2016 Jan 6.

7.

LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.

Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.

Neuropathol Appl Neurobiol. 2008 Jun;34(3):272-83. Epub 2007 Oct 26.

8.

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG.

Neurobiol Dis. 2010 Oct;40(1):73-81. doi: 10.1016/j.nbd.2010.04.002. Epub 2010 Apr 9.

9.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
10.

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM.

Hum Mol Genet. 2007 Jan 15;16(2):223-32. Epub 2007 Jan 2.

PMID:
17200152
11.

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ.

PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.

12.

Modeling Parkinson's disease using induced pluripotent stem cells.

Byers B, Lee HL, Reijo Pera R.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42. doi: 10.1007/s11910-012-0270-y. Review.

13.

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13.

14.
15.

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Moore DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8. doi: 10.1016/j.parkreldis.2008.04.010. Epub 2008 Jul 7. Review.

PMID:
18602856
16.

LRRK2 and neurodegeneration.

Santpere G, Ferrer I.

Acta Neuropathol. 2009 Mar;117(3):227-46. doi: 10.1007/s00401-008-0478-8. Epub 2009 Jan 14. Review.

PMID:
19142648
17.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

18.

14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Lavalley NJ, Slone SR, Ding H, West AB, Yacoubian TA.

Hum Mol Genet. 2016 Jan 1;25(1):109-22. doi: 10.1093/hmg/ddv453. Epub 2015 Nov 5.

19.

Cellular effects of LRRK2 mutations.

Cookson MR.

Biochem Soc Trans. 2012 Oct;40(5):1070-3. Review.

20.

Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.

Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, Stankowski J, Kim MS, Zhong J, Kumar M, Andrabi SA, Xiong Y, Dickson DW, Wszolek ZK, Pandey A, Dawson TM, Dawson VL.

Cell. 2014 Apr 10;157(2):472-85. doi: 10.1016/j.cell.2014.01.064.

Supplemental Content

Support Center